PNPT1 and PCGF3 variants associated with angiotensin-converting enzyme inhibitor-induced cough: a nested case-control genome-wide study.

Guangyan Mu,Qian Xiang,Zhuo Zhang,Chengzhang Liu,Hanxu Zhang,Zhiyan Liu,Xiaocong Pang,Jie Jiang,Qiufen Xie,Shuang Zhou,Zining Wang,Kun Hu,Zhe Wang,Shanqun Jiang,Xianhui Qin,Yimin Cui
DOI: https://doi.org/10.2217/pgs-2019-0167
2020-01-01
Pharmacogenomics
Abstract:Aim: We aimed to identify genetic variants associated with ACE inhibitor (ACEI)-induced cough. Materials & methods: A nested case-control study was performed among hypertensive Chinese patients receiving enalapril-only therapy. Whole-exome sequencing and genome-wide association analysis were performed. Results: We identified that PNPT1 rs13015243 (odds ratio [OR]: 0.47; 95% CI: 0.34-0.66; p = 7.45 x 10(-6)), PNPT1 rs13009649 (OR: 0.48; 95% CI: 0.35-0.67; p = 9.96 x 10(-6)) and PCGF3 rs1044147 (OR: 2.67; 95% CI: 1.71-4.17; p = 9.91 x 10(-6)) were significantly associated with ACEI-induced cough. Nearly genome-wide significant associations in previously reported candidate risk genes CLASP1, ACE, CES1, CPN1, XPNPEP1, PDE11A or SLC38A were detected in our dataset. Conclusion: Our results suggest that ACEI-induced cough is associated with noncoding SNPs of PNPT1 and PCGF3, all of which are independent of the bradykinin pathway.
What problem does this paper attempt to address?